MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting
MEI Pharma, Inc. (NASDAQ: MEIP) will host a video webcast for investors and analysts on June 10, 2021, at 12:00 PM ET, following the 2021 ASCO Annual Meeting. The event will cover updates on the zandelisib program, including data presented at ASCO, with insights from Dr. Deepa Jagadeesh of the Cleveland Clinic. The webcast can be accessed on MEI's investor relations website, and a replay will be available for 30 days. MEI focuses on developing innovative cancer therapies and has four clinical-stage assets, including zandelisib, which is in a Phase 2 trial.
- None.
- None.
SAN DIEGO, June 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will host an investor and analyst video webcast event on Thursday, June 10, 2021 at 12:00 PM ET following the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will include a review of the zandelisib program, including recent data presented at ASCO, and commentary from key opinion leader Deepa Jagadeesh, M.D., MPH, a board-certified medical oncologist/hematologist and assistant professor, Cleveland Clinic Lerner College of Medicine, Lymphoma and Bone Marrow Transplant Program, and Taussig Cancer Institute. The event will include additional zandelisib data as well as an overview and update of MEI's business.
Video Webcast Information
You can access the live video webcast under the investor relations section of MEI's website on the "Events and Presentation" page at: www.meipharma.com. A replay of the video webcast will be archived for at least 30 days after the conclusion of the live event.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support accelerated approval applications with the U.S. Food and Drug Administration. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com. Follow us on Twitter @MEI_Pharma and on LinkedIn.
Forward-Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mei-pharma-to-host-investor-and-analyst-video-webcast-event-following-2021-asco-annual-meeting-301305772.html
SOURCE MEI Pharma, Inc.
FAQ
What is the date and time for MEI Pharma's webcast on zandelisib?
Who will present information during the MEI Pharma webcast?
What key topics will be discussed in the MEI Pharma webcast?
How can I access the MEI Pharma webcast?
What is zandelisib and its current trial phase?
Will there be a replay available for the MEI Pharma webcast?
